Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2018-09, Vol.29, p.vi23-vi23
Hauptverfasser:	Guney Eskiler, G., Cecener, G., Egeli, U., Tunca, B.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	vi23
container_issue
container_start_page	vi23
container_title	Annals of oncology
container_volume	29
creator	Guney Eskiler, G. Cecener, G. Egeli, U. Tunca, B.
description
doi_str_mv	10.1093/annonc/mdy314.008
format	Article
fullrecord	<record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy314_008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419323026</els_id><sourcerecordid>S0923753419323026</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2308-f29756fc5e356beb498699fd68753f7ebbbf599bdbd7fd27153ce1e5a303d5223</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAWyQlyA11I86icUqVLykAlUF68iPCRi1SWWnhfL1GAVYspoZzdyruQehY0rOKZF8pOq6qc1oabecjs8JyXdQn4pUJjkZ013UJ5LxJBN83EMHIbwRQlLJ5D7qcUazLGW0jz6KEBrjVOuaGl_OJwVerttuCrGuA9bQvgPE5f0DTjOOT1u1UJ_NSnmnz4ZY1bjxaoFnxXyGXf3qtGsbP4wtbr1bLSCp4SUabgBrDyq02KjagD9Ee5VaBDj6qQP0fH31NLlNpo83d5NimhjGSZ5UTGYirYwALlINeizzVMrKpnnMVWWgta6ElNpqm1WWZVRwAxSE4oRbwRgfINr5Gt-E4KEqV94tld-WlJTfFMuOYtlRLCPFqDnpNKu1XoL9U_xiiwcX3QHEzzcOfBmMgxjLOg-mLW3j_rH_AhulhXc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Guney Eskiler, G. ; Cecener, G. ; Egeli, U. ; Tunca, B.</creator><creatorcontrib>Guney Eskiler, G. ; Cecener, G. ; Egeli, U. ; Tunca, B.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy314.008</identifier><identifier>PMID: 32177621</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-09, Vol.29, p.vi23-vi23</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32177621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guney Eskiler, G.</creatorcontrib><creatorcontrib>Cecener, G.</creatorcontrib><creatorcontrib>Egeli, U.</creatorcontrib><creatorcontrib>Tunca, B.</creatorcontrib><title>Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EoqXwAWyQlyA11I86icUqVLykAlUF68iPCRi1SWWnhfL1GAVYspoZzdyruQehY0rOKZF8pOq6qc1oabecjs8JyXdQn4pUJjkZ013UJ5LxJBN83EMHIbwRQlLJ5D7qcUazLGW0jz6KEBrjVOuaGl_OJwVerttuCrGuA9bQvgPE5f0DTjOOT1u1UJ_NSnmnz4ZY1bjxaoFnxXyGXf3qtGsbP4wtbr1bLSCp4SUabgBrDyq02KjagD9Ee5VaBDj6qQP0fH31NLlNpo83d5NimhjGSZ5UTGYirYwALlINeizzVMrKpnnMVWWgta6ElNpqm1WWZVRwAxSE4oRbwRgfINr5Gt-E4KEqV94tld-WlJTfFMuOYtlRLCPFqDnpNKu1XoL9U_xiiwcX3QHEzzcOfBmMgxjLOg-mLW3j_rH_AhulhXc</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Guney Eskiler, G.</creator><creator>Cecener, G.</creator><creator>Egeli, U.</creator><creator>Tunca, B.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201809</creationdate><title>Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer</title><author>Guney Eskiler, G. ; Cecener, G. ; Egeli, U. ; Tunca, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2308-f29756fc5e356beb498699fd68753f7ebbbf599bdbd7fd27153ce1e5a303d5223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guney Eskiler, G.</creatorcontrib><creatorcontrib>Cecener, G.</creatorcontrib><creatorcontrib>Egeli, U.</creatorcontrib><creatorcontrib>Tunca, B.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guney Eskiler, G.</au><au>Cecener, G.</au><au>Egeli, U.</au><au>Tunca, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-09</date><risdate>2018</risdate><volume>29</volume><spage>vi23</spage><epage>vi23</epage><pages>vi23-vi23</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32177621</pmid><doi>10.1093/annonc/mdy314.008</doi><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0923-7534
ispartof	Annals of oncology, 2018-09, Vol.29, p.vi23-vi23
issn	0923-7534 1569-8041
language	eng
recordid	cdi_crossref_primary_10_1093_annonc_mdy314_008
source	EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title	Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20BRCA%20mutation%20status%20between%20BMN%20673%20(talazoparib),%20an%20oral%20PARP%20inhibitor,%20in%20triple-negative%20breast%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Guney%20Eskiler,%20G.&rft.date=2018-09&rft.volume=29&rft.spage=vi23&rft.epage=vi23&rft.pages=vi23-vi23&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy314.008&rft_dat=%3Celsevier_cross%3ES0923753419323026%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32177621&rft_els_id=S0923753419323026&rfr_iscdi=true